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Abstract
Hepatocellular carcinoma is mainly associated with viral hepatitis B and C. Activation of cell growth stimulator IGF-II
gene is observed in tumor formation especially in viral associated hepatocellular carcinoma. Elevated IGF-II levels
are indicator of increased risk for cholangiocellular and hepatocellular carcinomas through over saturation of IGF-II
binding capacities with IGF receptors leading to cellular dedifferentiation. In HCV, core protein is believed to trans-
activate host IGF-II receptor through PKC pathway and the inhibition of tumor cell growth can be achieved by
blocking IGF-II pathway either at transcriptional level or increasing its binding with IGFBPs (Insulin like growth
factor proteins) at C-terminal, so that it is not available in free form. IGFBP-6 is a specific inhibitor of IGF-II actions.
Affinity of IGFBPs with IGFs is controlled by post-translational modifications. Phosphorylation of IGFBPs inhibits IGFs
action on target cells while O-glycosylation prevents binding of IGFBP-6 to glycosaminoglycans and cell
membranes and resulting in a 10-fold higher affinity for IGF-II. O-glycosylation and phosphorylation operate the
functional expression of cellular proteins, this switching on and off the protein expression is difficult to monitor in
vivo. By using neural network based prediction methods, we propose that alternate O-b-GlcNAc modification and
phosphorylation on Ser 204 control the binding of IGFBP-6 with IGF-II. This information may be used for
developing new therapies by regulating IGFBP-6 assembly with IGF-II to minimize the risk of viral associated
hepatocellular carcinoma. We can conclude that during HCV/HBV infection, O-b-GlcNAc of IGFBP-6 at Ser 204
diminish their binding with IGF-II, increase IGF-II cellular expression and promote cancer progression which can
lead to hepatocellular carcinoma. Furthermore, this site can be used for developing new therapies to control the
IGF-II actions during viral infection to minimize the risk of hepatocellular carcinoma.
Introduction
Among the highly malignant human tumors, hepatocel-
lular carcinoma is the most common. It is the fifth most
prominent tumor in the world and is the third most
widespread cause of cancer-related death [1]. HCC pro-
gression is a multi-step process along with multiple fac-
tors based etiology. Major risk factors contributing to
HCC include HCV and HBV infection along with alco-
hol intake and metastasis of cancer in other parts of the
body like colon [2]. The malignant transformation pro-
cess is influenced by a number of growth factors, recep-
tors and other related proteins. Among these related
proteins, IGF axis is one of the very important disease
contributors [3]. The insulin-like growth factor (IGF)
system regulates growth, development and function of
glands through complex interactions with other growth
factors and hormones [4]. IGF has structure similarities
to insulin [5]. IGF system is composed of two ligands
(polypeptide growth factors, IGF-I and IGF-II), two
receptors (IGF-IR and IGF-IIR), and six high-affinity
binding proteins (IGFBPs) [6]. IGFs bind to a number of
proteins including insulin receptors (IGF-I receptor and
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their biological actions by interacting with specific
receptors localized on the cell membrane [7,8].
IGF-I binds with high affinity to IGF-I receptor
whereas IGF-II binds with IGF-II receptor more effec-
tively [9]. IGF-II responses are mediated by G-proteins
singling. IGF-II receptor stimulates cellular responses
like proliferation and motility when interact with IGF-II
[10]. IGF-II has cell replication promoting effects and is
also termed as multiplication stimulating activity (MSA)
[11]. IGF-II is closely related to insulin like fetal growth
peptide produced by liver. In a variety of neoplasms
IGF-II is reported to be highly over expressed [12].
Furthermore aberrant IGF-II expression is also thought
to be involved in liver carcinogenesis [13]. High concen-
tration of IGF-II is also been found in the cancerous
liver cell lines i.e. Huh-7 and HepG2. While IGF-II
transgenic mice showed increased risk of HCC [14,15].
Recently IGF-II has been proposed as serum marker of
human HCC [16]. In case of hepatocarcinogenesis,
increased expression of IGF-II, protease activity of IGF-
binding proteins and IGF-I receptor along with down
regulation of IGF-II receptor is considered to play an
important role in the disease progression [14]. In HCV-
related cirrhosis patients there is significant increase in
the IGF-II expression which clearly indicates its strong
link with HCV [7]. In HCV chronic hepatitis the contin-
uous process of hepatocytes damage and regeneration
can possibly inflame uncontrolled growth of hepatocytes
leading to malignant transformations possibly due to
aberrant growth regulation or mitogenic factors disrup-
tion [17]. The exact mechanism of correlation of HCV
and IGF-II deregulation is still not fully understood.
IGFBP-6 an important member of IGFBPs family is a
relatively specific inhibitor of IGF-II actions. IGFBP has
the highest affinity among IGFBPs to bind with IGF-II
along with 20 to 100 fold preference of binding to IGF-
II rather than IGF-I. Non proliferative state is usually
related with IGFBP-6 expression. IGFBP-6 expression is
generally stimulated by different agents like retinoic acid
[18]. It consists of three domains of equal size. The N
and C-terminals are internally sulfide linked and share a
high degree of sequence homology across the IGFBPs
family [18,19]. The C-domain of IGFBP-6 reacts with
IGF-II at thyroglubulin type 1 fold [20]. The IGFII binds
itself on IGFBP-6 hydrophobic end located between a-
helix and the first and second loop of the first strand.
Many amino acid residues on the surface like, Val178,
Ser203, Ser 204, Gly206, Ala182 and Pro188 are also
considered as the binding supporter of the IGFII. This is
still need to be confirmed experimentally [21].
Cell systems in which IGFBP-6 has been shown to
inhibit IGF-II induced effects such as proliferation, dif-
ferentiation, cell adhesion, and colony formation include
osteoblasts, keratinocytes, myoblasts, and colon cancer
cells [22]. Post-translational modifications (PTM) regu-
late the affinity of IGFBPs for IGFs and this is the prin-
cipal mechanism involved in regulating IGF
bioavailability during folliculogenesis [23]. IGFBP-6
undergoes a number of posttranslational modifications,
including proteolytic cleavage, phosphorylation and gly-
cosylation [24]. Phosphorylation of IGFBP-6 leads to
change its affinity with IGFs and it inhibits IGF-II action
on target cells [7,22]. Glycosylation is also very much
known PTM in IGFBPs especially in IGFBP-6 in human,
rat and mouse [19,20,24]. O-glycosylation prevents bind-
ing of IGFBP-6 to glycosaminoglycans and cell mem-
branes and resulting in a 10-fold higher affinity for IGF-
II. O-glycosylation also delays and resists the proteolysis
of IGFBP by chymotrypsin and trypsin than non-glyco-
sylated IGFBP-6 [19,20].
It has been documented but not extensively studied
that high levels of IGF-II in hepatocellular carcinoma
can be control by parental imprinting or changes in
methylation pattern in IGF-II genes [25]. In this study
we describe another phenomenon that may regulate
IGF-II functions through post-translational modifica-
tions in IGFBP-6. We describe potential phosphorylation
and O-b-GlcNAc sites, and their possible interplay in
IGFBP-6 leading to change affinity with IGF-II and
modify the functions of IGF-II, which have been pre-
dicted and analyze using different prediction methods
available. On the basis of potential phosphorylation and
glycosylation interplay in conserved residues of IGFBP-
6, the possible roles played by these post-translational
modifications in regulating the functions of IGFBP-6 are
analyzed.
Materials and methods
T h es e q u e n c ed a t au s e dt op r e d i c tp o t e n t i a lp h o s p h o r -
ylation and glycosylation sites of IGFBP-6 of Homo
sapiens was retrieved from the SWISS-PROT sequence
database [26]. The entry name was IBP-6 Human with
the primary accession number P24592. BLAST search
was made using NCBI database which finds regions of
local similarity among the sequences of proteins or
nucleotides, and can be used to elucidate evolutionary
relationships [27]. The search was performed on
known species of different mammals. Six IGFBP-6
sequences with highest bit score values were selected
as given in Table 1. The mammals selected were
Homo sapiens (Human, P24592), Mus musculus
(Mouse, P47880), Ovis aries (Sheep, B5AN56), Rattus
norvegicus (Rat, P35572), Sus sacrofa (Pig, A9NJ32)
and Bos taurus (Bovin, Q05718). All the six sequences
were multiple aligned using ClustalW [28]. ClustalW is
a general purpose multiple sequence alignment pro-
gram for DNA or protein.
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“MTPHRLLPPLLLLLALLLAASPGGALARCPGCGQG
VQAGCPGGCVEEEDGGSPAEGCAEAEGCLRREGQ
ECGVYTPNCAPGLQCHPPKDDEAPLRALLLGRGR
CLPARAPAVAEENPKESKPQAGTARPQDVNRRDQQR
NPGTSTTPSQPNSAGVQDTEMGPCRRHLDSVLQQ
LQTEVYRGAQTLYVPNCDHRGFYRKRQCRSSQGQ
RRGPCWCVDRMGKSLPGSPDGNGSSSCPTGSSG”.
Prediction of post-translational modifications
Prediction of phosphorylation residues and related kinases
Phosphorylation potential for human IGFBP-6 was pre-
dicted by using NetPhos 2.0 (http://www.cbs.dtu.dk/ser-
vices/NetPhos/) server [29]. This is a neural network-
based program that predicts the potential phosphoryla-
tion sites for each Thr, Ser and Tyr residues. The mini-
mum threshold value used to predict phosphorylation is
0.5. Disphos 1.3 (http://www.ist.temple.edu/disphos/)
server [30] was also used for the prediction of possible
phosphorylation sites in human IGFBP-6.
Kinase specific phosphorylation sites in human
IGFBP-6 were predicted by NetPhosK 1.0 server (http://
cbs.dtu.dk/services/NetPhosK) [31]. The NetPhosK 1.0
predicts the kinase specific acceptor substrates including
Ser, Thr and Tyr. KinasePhos 2.0 (http://kinasephos.
mbc.nctu.edu.tw/case2.html) server [32] was also used
for kinase prediction.
For the purpose of evaluating experimentally verified
phosphorylation sites on human IGFBP-6, Phospho.ELM
database (http://phospho.elm.eu.org) was used [33]. This
database contains a collection of experimentally con-
firmed Ser, Thr and Tyr residues in eukaryotic proteins.
Prediction of o-glycosylated residues and YinOYang sites
O-b-GlcNAc modification potential sites can be pre-
dicted by YinOYang 1.2 (http://www.cbs.dtu.dk/services/
YinOYang/). This program can predict the potential
phosphorylation sites as well and hence predicting the
Yin-Yang sites with highly uneven threshold that is
adjusted in accordance with amino acid surface accessi-
bility [34-37]. We also used OGPET (http://ogpet.utep.
edu/OGPET/) [38] for predicting O-glycosylation at Ser
and Thr residues.
Protein structure analysis
As there was no template model of IGFBP-6 available in
protein data bank [39], we designed an ab-initio model
by using software I-TASSER (http://zhanglab.ccmb.med.
umich.edu/I-TASSER/) [40]. Data in sequence form was
uploaded to the server. Model with high C-score was
selected as ab-initio model. To view and analyze 3D
structure Jmol (http://jmol.sourceforge.net/) [41] and
PYmol (http://www.pymol.org/export) [42] programs
w e r eu s e d .T oa s s e s s ,w h e t h e rt h ep r e d i c t e dS e ra n d
Thr residues have surface accessibility for post-transla-
tional modifications, NetSurfP (http://www.cbs.dtu.dk/
services/NetSurfP/) was used [43]. We also used Scan-
site server (http://scansite.mit.edu/motifscan_seq.phtml)
to check surface ability of IGFBP-6 to solvents and for
PTMs [44].
Neural networks-based prediction methods
Above described prediction methods are artificial neural
network-based and have been extensively used in pre-
dicting the potentials of proteins for post-translational
modifications and in biological sequence analysis [45].
These methods are designed by memorizing the known
sequence environment data of glycosylated/phosphory-
lated Ser/Thr and non-glycosylated/non-phosphorylated
Ser/Thr sites. The results obtained from all the net-
works are sigmoidally arranged and averaged to obtain a
value between zero and one by these prediction meth-
ods. Usually a threshold of 0.5 is used for prediction,
which means that a site with an output of more than
0.5 is assigned as having a potential to be glycosylated
or phosphorylated. NetPhos 2.0 predicts phosphoryla-
tion on the OH- function of Ser, Thr or Tyr residues
with a sensitivity range of 69-96%. YinOYang 1.2
employed the sequence data to train a jury of neural
networks on 40 experimentally determined O-GlcNAc
acceptor sites for recognizing the sequence context and
surface accessibility. This method is efficient in a cross
validation test as it correctly identifies 72.5% of the gly-
cosylated sites and 79.6% of the non-glycosylated sites
in the test set, verifying the Matthews correlation coeffi-
c i e n to f0 . 2 2o nt h eo r i g i n a ld a t a ,a n d0 . 8 4o nt h ea u g -
mented data set. This method has the capability to
predict the YinOYang sites that can be glycosylated and
alternatively phosphorylated on Ser/Thr or Tyr residues.
Results
Alignment of sequences for the determination of
conserved status of Ser/Thr residues within IGFBP-6
To determine conserved and conserved substituted Ser
and Thr residues within each subtype, human IGFBP-6
protein FASTA sequence was aligned with other mam-
mals (Figure 1). It is clear from the figure that Ser 120,
144, 169, 203, 204, 225 and 239; and Thr 143 and 176
were highly conserved in mammals. Meanwhile, Ser 231
Table 1 Different IGFBP-6 proteins used for multiple
alignment
Species name Accession no. Identity Score E-Value
Human (Homo sapiens) P24592 100% 1,322 1.0 × 10
-144
Pig (Sus scrofa) A9NJ32 84% 1,101 1.0 × 10
-118
Bovin (Bos taurus) Q05718 83% 1,079 1.0 × 10
-116
Sheep (Ovis aries) B5AN56 82% 1,054 1.0 × 10
-113
Mouse (Mus musculus) P47880 70% 880 1.0 × 10
-92
Rat (Rattus norvegicus) P35572 66% 783 2.0 × 10
-81
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conserved substitutions within mammals.
Acquiring experimentally verified S/T/Y residues
Data for experimentally confirmed S/T/Y residues was
searched from Phospho.ELM (http://phospho.elm.eu.
org) and UniprotKB (http://www.uniprot.org). Although
all IGFBP sub forms are subjected to be phosphorylated,
however, there is no experimentally verified phosphory-
lation site.
Prediction of Phosphorylation Sites
Prediction results by NetPhos 2.0 for possible phosphor-
ylation sites revealed that IGFBP-6 possesses high
potential for phosphate modification like other subtypes.
15 phosphorylation sites at Ser, Thr and Tyr residues
were predicted. In IGFBP-6 there are 9 Ser, 4 Thr, and
2 Tyr residues that are subjected to phosphorylation as
shown in Figure 2.
Prediction of Kinases involved in Phosphorylation
Different kinases are involved in phosphorylation of
mammalian IGFBPs so specific phosphorylation sub-
strate potential was assessed by using NetPhosK 1.0.
The results obtained from NetPhosK 1.0 had shown the
involvement of different kinases in phosphorylation of
predicted human IGFBP-6. PKC can phosphorylate Ser
(120, 169, 204 and 221) and Thr (126 and 176). Cdc2
can phosphorylate Ser (232, 233, and 239) and Thr (126
and 176). Similarly Cdk5 can phosphorylate Ser (225)
and Thr (2, 85 and 146). CK II can phosphorylate Ser
52, PKA phosphorylate serine 120, DNAPK and ATM
both can phosphorylate serine 144 and 204. EGFR can
phosphorylate Tyr 179 and 196 while GSK3 can phos-
phorylate Ser 221 and 225 respectively.
The other neural network based program Kinasephos
was also used to assess the possible kinases on IGFBP-6.
It also predicts many kinases that may be involved in
IGFBP-6 protein phosphorylation as given in Table 2.
Figure 1 Multiple alignments of six vertebrates sequences
(Human, Bovin, Sheep, Pig, Mouse and Rat). These different
sequences were ordered as aligned results from ClustalW. The
consensus sequence is marked by an asterisk, conserved
substitution by a double dot, and semi conserved substitution by a
single dot.
Figure 2 Graphic representation of the potential Ser, Thr, and
Tyr residues for phosphorylation and o-glycosylation
modification at human IGFBP-6. A) Predicted potential sites for
phosphate modification on Ser and Thr residues. The light gray
horizontal line indicates the threshold for modification potential.
The blue, green and red vertical lines show the potential
phosphorylated Ser, Thr and Tyr residues, respectively. B) Predicted
potential sites for o-glycosylation modification of Ser and Thr. O-b-
GlcNAc modification potential of Ser/Thr residues is shown by green
vertical line, while the light blue wavy line indicates the threshold
for modification potential. C) The Yin Yang sites that were positively
predicted are shown with red asterisk at the top, while the NP-Yin-
Yang sites are shown with purple asterisk on the top of vertical
lines. The green vertical lines show the O-b-GlcNAc potential of Ser/
Thr residue and the light blue horizontal wavy line indicates the
threshold for modification potential.
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The O-GlcNAc modification is known to be dynamic
and analogous to phosphorylation. The prediction
results obtained from YinOYang 1.2 for O-b-GlcNAc
showed that there are many high potential O-b-GlcNAc
sites for O-linked modifications. The human IGFBP-6
has 12 potential sites for O-b-GlcNAc modifications at
Ser 144, 148, 152, 204, 231, 232, 233, 238 and 239 and
at Thr 143, 146 and 236, with five Yin-Yang sites
marked by asterisk (Figure 2).
OGPET also predict possible O-GlcNAc Ser and Thr
sites. These are given in Table 2. These sites were
almost same as predicted by YinOYang server.
Identification of False-Negative Sites
There were 5 Yin Yang sites according to the prediction
results (Ser: 144, 148, 152, 204 and Thr 146). Besides
these, there were many other Ser and Thr residues that
were predicted to be non-glycosylated, but the phos-
phorylation potential predicted was either much higher
than the threshold value or very close to it. These are
also conserved residues in mammals. Such residues
appear to be as false-negative sites. These may act as
possible Yin Yang sites other than those which have
been predicted by the YinOYang 1.2 method. According
to our results these sites may be Ser 120 and 169; and
Thr 75 and 126 (Table 3).
Discussion
Many studies have tried to find out the role of host fac-
tors in causing hepataocellular carcinoma linked to HBV
and HCV. One of the factors mediating the HCV and
HBV associated hepatocellular carcinoma is IGFs. HBV
stimulate the expression of IGF-IR and modulate the
Table 2 Predicted phosphorylation and O-glycosylation sites on IGFBP-6 protein
Substrate Position Phosphorylation
prediction
Kinase prediction O-glycosylation
prediction
Surface
accessibility
Netphos Disphos NetphosK Kinasephos YinOYang OGPET Scansite NetSurfP
Thr 2 Y Y MAPK, CDK5 - N LP - E
Ser 21 Y N MAPK, CDC2, GSK3 CAM2, CDC2, MAPK, CDK N LP - B
Ser 52 Y Y CK2 CDC2, ATM, IKK N VHP <1 E
Thr 75 P Y MAPK, CDK5 CDK N VHP <1 E
Ser 120 Y Y PKC, PKA PKG, CKI N LP - E
Thr 126 Y Y PKC, CDC2 PKC N VHP - E
Thr 143 N N - MDD Y VHP - E
Ser 144 Y Y - PKC, CDC2 Y HP >1 E
Thr 145 P Y PKC CDK, MDD Y HP >1 E
Thr 146 Y Y CDK5 CDC2, CDK Y HP >1 E
Ser 148 Y Y DNAPK, ATM PKA, CKI, ATM Y HP >1 E
Ser 152 Y N - CDC2, IKK Y VHP - E
Thr 158 P N - CK2 N LP - E
Ser 169 Y N PKC CAM2, CKI, IKK N LP <1 E
Thr 176 N Y PKC PKC N LP - E
Thr 184 Y N PKC PKC N LP - E
Ser 203 P Y - CKI, CDC2, IKK N VHP - E
Ser 204 Y Y PKC, ATM, DNAPK ATM Y HP >1 B
Ser 221 P Y GSK3 PKG, IKK N LP <1 B
Ser 225 Y Y GSK3 CDC2, CDK, ATM N LP >1 B
Ser 231 P Y - CDC2, CDK Y VHP - E
Ser 232 N Y CDK5 IKK, PKB Y NHP <1 B
Ser 233 P Y CDC2 IKK Y HP <1 E
Thr 236 N Y CDC2 - Y VHP - E
Ser 238 N Y - - Y - - E
Ser 239 N Y CDC2 - Y HP - E
Y = yes (threshold >0.5), P = probable (threshold > 0.1~0.5), N = No (threshold <0.1), VHP = very high potential (threshold ≥1.0), HP = high potential (threshold
>0.8 <1.0), LP = low potential (threshold <0.8), <1 = low surface accessibility, >1 = high surface accessibility, 1 = low potential for solvent accessibility, 2 = high
potential for solvent accessibility, B = Buried surface, E = Exposed surface,
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Whereas, in HCV associated hepatocellular carcinoma
IGFII expression is activated by fetal promoters. HCV
core protein has been found to increase the expression
of IGFII through PKC pathway and plays role in HCV
pathogenesis in inducing hepatocellular carcinoma [46].
Post-translational modifications in proteins play very
important role in regulation of their functions and
induce conformational changes that allow the protein to
interact with other proteins [47,48]. Binding of IGFBP-6
with IGF-II inhibits IGF-II binding with cell surfaces
(receptors) and decrease its affinity for proteolysis. Pro-
teolysis of IGFBPs decreases their binding affinities with
IGFs [20] and O-glycosylation of IGFBP-6 enhances its
resistance to proteolysis by chymotrypsin and trypsin
[19]. The IGFBP interaction with IGF can change from
ah i g ha f f i n i t ys t a b l ec o m p l e xt oah i g h l yl a b i l eo n e
when IGF release is required. In the tissues, the release
of IGFs from the IGFBPs can be modulated by three
mechanisms; which function to decrease the affinity of
the IGFBPs to the IGFs and act as a sustaining local
source of IGFs to the IGF receptors. The first mechan-
ism is association of the IGFBPs to the extracellular
matrix (ECM) or specific cell membranes, second is the
cleavage of the IGFBPs by specific proteases, and third
is dephosphorylation [49].
Ser residues in the mid region of the IGFBP-6 are the
main target of the phosphorylation. Headey et al (2004)
found that the IGF-II binding site is located on C-term-
inal of IGFBP-6 from Leu 174, Gly 206 [21]. Regulation
of IGF bioavailability, binding of IGFs to IGFBPs is
modulated by phosphorylation process [22]. Phosphory-
lation of human IGFBPs enhances both its affinity for
IGFs and their capacity to inhibit IGFs actions [50]. A
phosphorylation site of IGFBP-6 at Thr-126 is described
by Baxter and Firth which is phosphorylated by enzyme
PKC
c and it is also a Yin Yang site [51]. Our Netphos
1.0 and Disphos results showed that IGFBP-6 has high
potential for phosphorylation at middle and C-terminal
region. As C-terminal of IGFBP-6 is involved as binding
site for IGF-II, we found that Ser 204 has high potential
for phosphorylation. It was also a conserved residue.
Our results of NetPhos K 1.0 and Kinasephos for the
prediction of phosphorylation potential of all Ser and
Thr residues showed that these residues are phosphory-
lated by different kinases during cell cycle as shown in
Table 2. These experimentally verified residues are
conserved in IGFBP-6 and we can assume that these
phosphorylated sites may be present on IGFBP-6 of
other mammals “by similarity” where these phosphoryla-
tion sites are not yet experimentally known. O-b-
GlcNAc modification can occur on these Ser and Thr
residues where kinases are involved in phosphorylation
as it is well known that kinases and OGT can compete
for same site modification [34-37,52]. This shows a pos-
sibility for interplay between phosphorylation and OGT
on these residues. O-glycosylation is known and experi-
mentally verified post-translational modification in
IGFBP-6 [53]. YinOYang 1.2 and OGPET prediction
results had shown that IGFBP-6 have high potential for
O-linked glycosylation (Figure 3).
The Ser and Thr residues of IGFBP-6 which are pre-
dicted to be phosphorylated and also showed positive
potential for O-b-GlcNAc modification are Ser-144, 148,
Table 3 Proposed Ser/Thr residues for interplay of phosphorylation and O-GlcNAc modification in Homo sapiens
IGFBP-6
SUBSTRATE Predicted Yin Yang sites Proposed FN-Yin Yang sites Proposed Yin Yang sites Yin Yang sites by similarity
IGFBP-6 Ser 144, 148, 152, 204 120, 169 204 -
Thr 146 75, 126 -
Figure 3 A homology model of human IGFBP-6 utilizing
automated protein modeling option was retrieved through I-
TASSER server. Five models were received from the server utilizing
five different templates namely: model 1-5 through this option.
Among the five, one that covered all amino acids with alpha helix
structure and beta pleated sheet, high resemblance with
experimentally determined C-terminal and high C-value was
selected. This model shows that predicted Yin Yang sites have high
surface accessibility for the phosphorylation and O-b-GlcNAc
interplay. The Ser and Thr residues are denoted by red and green
colors respectively.
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prediction results showed that there are many Ser and
Thr residues which are not predicted as Yin Yang but
have high potential for phosphorylation, same as;
YinOYang 1.2 and OGPET also predicted such type of
residues to have high potential for O-b-GlcNAc modifi-
cation (Table 1). These predicted sites can also be phos-
phorylated by different kinases (Table 2) and act as
possible Yin Yang sites for O-b-GlcNAc modification
(Table 3). These remaining Ser and Thr residues of
IGFBP-6 which are conserved in different species and
either known or predicted to be phosphorylated, showed
negative potential for O-b-GlcNAc modification but
very close to threshold value are known as false-negative
Yin Yang (FN-Yin Yang) sites (Table 3). These con-
served sites can be accessed by different kinases so that
these sites have also strong possibility for OGT access
and thus can also act as source of interplay for phos-
phorylation and O-b-GlcNAc [34-37]. In our study, Ser
120 and 169, and Thr 75 and 126 are predicted as FN-
Yin Yang sites.
IGFBP-6 regulates biological processes such as cell
proliferation or growth arrest [54]. Overexpression of
IGFBP-6 in cancer cells activates programmed cell death
[55]. O-glycosylation at mid region leads to free IGFBP-
6 state by inhibiting binding to glycosaminoglycans and
by protecting against proteolysis. Both glycosaminogly-
can binding and proteolysis of IGFBP-6 decreases its
binding affinity for IGF-II. As we know that C- domains
of IGFBP-6 contains the binding sites and bind with
IGF-II receptor with high affinity. Post translational
modifications in the binding sites of IGFBP-6 change its
affinity with IGF-II and glycosaminoglycans [21]. The
mutations in C-terminal domain of IGFBP-6 result in
reduction for IGF-II binding affinity. The Ser 203, Ser
204 and Gln 205 contribute to the IGF-II binding pre-
ference of IGFBP-6. The proximity of the IGF-II and
glycosaminoglycan binding sites provides a structural
basis for the decrease in IGF binding affinity after
IGFBP-6 interaction with glycosaminoglycans. IGFBP-6
also has putative PKC site in C-terminal [22]. Ser 204 is
conserved residue in mammals. Our results indicate that
Ser 204 has high potential for phosphorylation and it
can be phosphorylated by PKC. Ser 204 is also a Yin
Yang site and has high potential for O-glycosylation.
The sites needed for IGF-II binding of IGFBP-6 are pre-
sent in C-terminal. In the binding sites at C-terminal of
IGFBP-6 there are two Ser residues 203 and 204. Our
results showed that only Ser 204 residue is conserved
and has ability to be phosphorylated and glycosylated.
To verify possible Yin Yang sites, we sketched the 3D
structure of IGFBP-6 protein (Figure 3). We evaluated
the surface accessibility of IGFBP-6 for these post trans-
lational modifications (Table 2). We found that Ser 204
was predicted as “Buried” by Netsurf P server, while
scan site showed high accessibility for solvents [56].
This problem was resolved by assessing the experimen-
tally determined 3D structure of C-terminal deposited
by Headey et al (2004). We were amazed to see that our
predicted full length IGFBP-6 3D structure having the
same C-terminal as experimentally proved by Heedy et
al. (2004), and it clearly showed that Ser 204 of IGFBP-6
is accessible for these types of modifications (Figure 3).
As we know that there is competition between O-gly-
cosylation and phosphorylation on Ser and Thr residues
[57], we therefore, propose that O-b-GlcNAc and phos-
phate modifications at Ser 204 residue control the bind-
ing of IGFBP-6 with IGF-II, while O-glycosylation and
phosphorylation on middle region Ser and Thr residues
control the binding of IGFBP-6 with glycosaminogly-
cans. Since IGFBP-6 has shown an inhibitory effect on
IGF functions in many cancer cell lines for example in
human breast cancer, so reduced IGFBP-6 levels can
therefore, affect cell growth in multiple ways, such as
increasing IGF bioavailability and reducing IGF indepen-
dent growth inhibitory effects etc. So we can conclude
that due to O-b-GlcNAc modification at Ser 204, bind-
ing of IGFBP-6 with IGF-II reduced and resulting in
binding of IGF-II with IGF-II receptor and promote
cancer progression which can lead to hepatocellular car-
cinoma in HCV infected patients (Figure 4). The
Figure 4 Schematic diagram illustrating the role of IGFBP-6
phosphorylation and O-glycosylation on IGF-II functions. Here
we propose that alternative O-b-GlcNAc modification and
phosphorylation of Ser 204 control the binding of IGF-II with IGFBP-
6 during viral infection, while mid region phosphorylation and O-b-
GlcNAc modifications controls it’s binding with glycosaminoglycans.
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Page 7 of 9application of such predictive techniques may be of
interest to develop therapeutics to decrease the hepato-
cellular carcinoma in cases with HCV and HBV-related
chronic hepatitis.
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